FeesSafety
Pluang+

Silicom reports 71% revenue growth and returns to non-GAAP profitability in Q3 2026, raising full-year revenue forecast.

Company Fundamentals
29 Oct 2026, 15:15 WIB
PRNewsWire
View Source
Bullish
Silicom reports 71% revenue growth and returns to non-GAAP profitability in Q3 2026, raising full-year revenue forecast.

Silicom Ltd. announced a 71% revenue increase to $26.7 million in Q3 2026, driven by strong Design Win momentum. The company returned to non-GAAP profitability with a net income of $0.3 million, a significant improvement from last year's loss. For the first nine months, revenues rose 55% to $69.6 million, with ongoing improvements in net losses. Silicom raised its full-year 2026 revenue guidance to $96-$98 million, expecting continued growth fueled by its expanding product portfolio and strategic investments in AI inference technologies.

Silicom's Q3 2026 revenue surged 71% to $26.7 million, highlighting strong Design Win momentum. For readers following Technology-sector US stocks, here is Pluang's market snapshot as of Oct 29, 2026 18:11 WIB: out of 150 priced stocks, 23 rose and 125 fell. Notable movers include FTNT at USD 127.94 with a 1-day change of -26.51% and 100% buy order activity, NOW at USD 120.15 with a -19.97% change and 93% sell order activity, and MRVL at USD 222.51 with an -11.58% change and 55% sell order activity.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App